Physician profile
Abdul Hafeez
NPI 1770593766
$13,053.49
in general payments reported to CMS, 2019-2025
17 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,976 · 2020: $3,085 · 2021: $651 · 2022: $404 · 2023: $597 · 2024: $869 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.61 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $8,506.67 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,158.59 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $686.79 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $389.01 | 2024-2025 | Cobenfy |
| Indivior INC. | $379.01 | 2019-2024 | Perseris |
| Otsuka America Pharmaceutical, INC. | $347.41 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $272.53 | 2019-2021 | |
| Allergan, INC. | $254.61 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.06 | 2021-2025 | Caplyta |
| Lundbeck LLC | $221.70 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $138.51 | 2019-2025 | Invega Sustenna |
| Abbvie INC. | $137.23 | 2021-2025 | |
| Axsome Therapeutics, INC. | $87.99 | 2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.29 | 2019-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $45.70 | 2024 | Restrata Wound Matrix |
| Validus Pharmaceuticals LLC | $22.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.